Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 9Carcinoma, Non-Small-Cell Lung 7Sarcoma 5Breast Neoplasms 4Triple Negative Breast Neoplasms 3Nasopharyngeal Carcinoma 3Thyroid Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Whole-Brain Radiotherapy 1Stomach Neoplasms 1Solid Tumors 1Small Cell Lung Cancer Extensive Stage 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Recurrence 1Proteinuria 1Progression Free Survival(PFS) 1Platinum-resistant Ovarian Cancer (PROC) 1Ovarian Neoplasms 1Lung Neoplasms 1Leiomyosarcoma 1HER2-Negative Breast Cancer 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Cancer 1Esophageal Neoplasms 1

Interventions

tislelizumab 1selinexor 1atezolizumab 1anlotinib 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Lung Small Cell Cancer × anlotinib × 1 year × Clear all
NCT07172412 2025-09-30

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
165 enrolled

Extensive Stage Lung Small Cell Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡